CGUK20101 / A031704 / Deepak Sahasrabudhe
Research Question:
How does the usual treatment (treatment with ipilimumab and nivolumab followed by
nivolumab alone) compare to treatment with ipilimumab and nivolumab followed by nivolumab
with cabozantinib in patients with untreated kidney cancer that has spread to other
parts of the body?
Basic Study Information
Purpose:
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab
followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed
by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that
has spread to other parts of the body. The addition of cabozantinib to the usual treatment
may make it work better. Immunotherapy with monoclonal antibodies, such as nivolumab
and ipilimumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known how well the combination of cabozantinib and nivolumab after initial treatment
with ipilimumab and nivolumab works in treating patients with renal cell cancer that
has spread to other parts of the body.
Location: University of Rochester Medical Center
Study Reference #: CGUK20101
Lead Researcher (Principal Investigator)
Lead Researcher:
Deepak Sahasrabudhe, MD
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search